Off-the-Shelf cell therapy takes on tough leukemia
NCT ID NCT07491263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new 'universal' cell therapy (QH103) for people with a hard-to-treat type of leukemia (B-ALL) that has come back or not responded to standard treatment. The therapy uses donor immune cells engineered to target cancer cells, given after chemotherapy to prepare the body. Only 6 participants will be enrolled to check safety and tolerability first.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QH103 Cell Injection (CD19 CAR-γδ T cells) with cyclophosphamide and fludarabine
- What this could lead to
- If it works, this could point toward a more accessible 'off-the-shelf' cell therapy for hard-to-treat leukemia, reducing the need for patient-specific treatments.
- What could go wrong
- This is a very early Phase 1 trial with only 6 people, focused on safety, not effectiveness. The therapy may not work, and there are risks like severe immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CD19-POSITIVE B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first affiliated hospital of fujian medical university
Fuzhou, Fujian, 350005, China